[Clinical and laboratory studies in patients with pulmonary tuberculosis treated with pyrazinamide]

Different combinations of tuberculostatic drugs containing pyrazinamide were prescribed to 144 patients with pulmonary tuberculosis. In 3 months of treatment, bacterial excretion was observed in 89.7% of newly diagnosed patients and in 59% of cases with chronic forms of pulmonary tuberculosis. Side effects due to pyrazinamide were registered in 16.8% of the patients. In 2-3 months of therapy there were no differences traced in the condition of the liver, lipoid peroxidation or antioxidative activity as well as in a number of immunologic indices both in subjects receiving different combinations of antituberculous drugs, containing pyrazinamide, and in the control group of patients untreated with the drug.